Stock Analysis
Rapport Therapeutics, Inc. Common Stock (RAPP) Stock Analysis
Rapport Therapeutics, Inc. Common Stock (RAPP) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
Rapport Therapeutics, Inc. Common Stock (RAPP) currently has an AIQ Score of 43/100, indicating a bearish setup. Quality is the strongest factor at 57/100. Momentum is the weakest current factor at 33/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
RAPP at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $26.15 |
| AIQ Score | 43/100 |
| Overall View | Bearish |
| Technical Analysis Consensus | Sell |
| Market Cap | $1.25B |
| P/E Ratio (TTM) | -8.25 |
| Forward P/E | — |
| EPS (Q3 FY2026) | -$0.84 |
| Revenue (Q3 FY2026) | $0 |
| Dividend Yield (TTM) | 0.00% |
| Beta | 1.27 |
| Volume | 316.12K |
| 52-week range | $22.06-$52.93 |
| RSI 14 | 44.91 |
| 50-Day SMA | $31.93 |
| 200-Day SMA | $35.59 |
| Analyst Price Target | $71.63 |
| Next Earnings | Mar 9, 2027 |
RAPPRapport Therapeutics, Inc. Common Stock
Healthcare / Biotechnology
Low Priority
Relative Laggard
Latest quote
- Momentum33
- Value42
- Quality57
- Risk resilience39
- Sentiment—
RAPP Stock Analysis Summary
Rapport Therapeutics, Inc. Common Stock (RAPP) currently has an AIQ Score of 43/100, indicating a bearish setup. Quality is the strongest factor at 57/100. Momentum is the weakest current factor at 33/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a bearish regime, RAPP has AIQ Score of 43/100 with Quality base of 57/100 and fading Momentum at 33/100. Wait for component alignment before adding exposure.
Quality (57/100) leads while Momentum (33/100) lags. This cross-factor spread creates entry timing uncertainty.
Healthcare · 1.16% stock move · RAPP classified in Biotechnology.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is RAPP Bullish or Bearish Right Now?
RAPP currently has a bearish overall setup. Quality is the strongest factor at 57/100, while Momentum is weakest at 33/100. The current evidence suggests a bearish setup.
- - Analyst target implies +173.90% upside from the latest quote.
- - Value is the current constraint at 42/100.
- - Momentum is weak at 33/100.
- - Risk Resilience is weak at 39/100.
- - Price is -26.52% below its 200-day SMA.
- - Technical consensus has more sell votes than buy votes (24 vs 15).
Current Consensus
RAPP's Technical Analysis Consensus is currently Sell, with 15 buy, 7 neutral, and 24 sell votes. RAPP's 14-day RSI is 44.91, which places the stock in a weaker momentum range. RAPP's beta is 1.27, indicating greater market sensitivity than the broad market.
What Changed in RAPP?
The largest recent change in RAPP is AIQ Score moving up by 1.0 points over the available 7-day comparison window. Quality remains the strongest visible factor.
What Would Change the RAPP Outlook?
The current bearish outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
RAPP Decision Framework
Public evidence layers, setup checks, and risk context for Rapport Therapeutics, Inc. Common Stock.
Rapport Therapeutics, Inc. Common Stock (RAPP) Stock Analysis
Rapport Therapeutics, Inc. Common Stock has an AIQ Score of 43/100 in a Bearish regime. Quality is strongest at 57/100. Beta is 1.27, above market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | RAPP is in a Bearish AIQ regime with score 43/100. |
| Signal Conflict | The primary conflict is that quality leads at 57/100 while momentum lags at 33/100. |
| Factor Evidence | Momentum 33/100 · Value 42/100 · Quality 57/100 · Risk 39/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Quality is the strongest factor at 57/100.
Momentum is 33/100 and RSI (14) is 44.9.
RAPP is in a Bearish regime at 43/100.
Risk factor is 39/100 with beta 1.27 and annual volatility 62.34%.
Current conflict: quality leads at 57/100 while momentum lags at 33/100.
RAPP Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
RAPP Fundamentals
RAPP valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
RAPP Technical Analysis
RAPP technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
RAPP Stock Catalysts
Track RAPP earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
RAPP Dividend Analysis
RAPP dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
RAPP Financial Data
RAPP revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
RAPP Risk Analysis
RAPP volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
RAPP Stock News
RAPP stock news, market tone, recent headlines, and catalyst context.
RAPP vs Biotechnology Peers
Current peer cohort: RAPP · RCUS · REPL · RLAY · RVMD. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| RAPP Current stock | 43/100 | 42/100 | 33/100 | 39/100 | 0.35 | 62.34% | Current |
| RCUS Arcus Biosciences, Inc. | 39/100 | 43/100 | 34/100 | 42/100 | 0.05 | 62.65% | RAPP vs RCUS |
| REPL Replimune Group, Inc. | 60/100 | — | 97/100 | 26/100 | 1.3 | 187.93% | RAPP vs REPL |
| RLAY Relay Therapeutics, Inc. | 56/100 | 37/100 | 76/100 | 52/100 | 1.84 | 65.80% | RAPP vs RLAY |
| RVMD Revolution Medicines, Inc. | 55/100 | 39/100 | 73/100 | 59/100 | 1.69 | 68.69% | RAPP vs RVMD |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
Also for RAPP: historical return with reinvested dividends and stock average calculator for several buys.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts8 recent quarterly periods are available for review.
Checked Nov 16, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Sep 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching RAPP
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for RAPP
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
RAPP Stock FAQ
What is RAPP stock price today?
Rapport Therapeutics, Inc. Common Stock's current stock price is $26.15. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is RAPP bullish or bearish right now?
RAPP's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is RAPP's market cap?
RAPP's market cap is $1.25B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is RAPP's current P/E ratio?
RAPP's current P/E ratio is -8.25 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is RAPP's RSI?
RAPP's 14-day RSI is 44.91 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is RAPP above its 50-day and 200-day moving averages?
RAPP is -18.10% from its 50-day SMA and -26.52% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is RAPP's next earnings date?
RAPP's next earnings date is currently listed as Mar 9, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does RAPP pay a dividend?
RAPP's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.